This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. G. COLLIER, M.D.; R. C. EY, M.D.; G. O. McDONALD, M.D.; W. H. COLE, M.D.

AMA Arch Surg. 1959;78(4):528-534.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the beginning of the clinical trial of the prophylactic or adjuvant treatment of cancer, we have been searching for topical anticancer agents which were not bone-marrow depressants. Such agents could be used locally (topically) for wound irrigation to kill cancer cells but would not add to the depression of the hematopoietic system caused by concomitant systemic use of anticancer drugs, such as mechlorethamine hydrochloride, N. F. (nitrogen mustard). In the experimental laboratory we had found that mechlorethamine and triethylenethiophosphoramide (ThioTEPA), both polyfunctioning alkylating agents, were effective in preventing the implantation of tumors in the liver following intraportal injection of tumor-cell suspensions.¹ As a result of this experimental work, we chose mechlorethamine as the agent to be used in the clinical trials of the administration of anticancer agents to the patient at the time of surgery. In other experimental work² we had determined that mechlorethamine, when diluted properly, . . . [Full Text PDF of this Article]

Author Affiliations
Chicago

From the Department of Surgery, University of Illinois College of Medicine.

Footnotes
Submitted for publication Oct. 27, 1958.

Supported in part by the University of Illinois Foundation and U. S. P. H. S. Grant CY 3482.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?